Join our WA MTP Sector Spotlight Series event with Proteomics International

01 April 2021

The MTPConnect WA Life Sciences Innovation Hub is hosting the next MTP Sector Spotlight Series event in Perth on Thursday, 29 April, and will shine a light on Proteomics International, a WA-based medtech company commercialising diagnostic tests for chronic diseases where there is unmet medical need.

MTPConnect’s Director Stakeholder Engagement WA Dr Tracey Wilkinson will be joined by Proteomics International's Founder and Managing Director Richard Lipscombe, where they will discuss his company’s experience developing a medtech product within Australia’s R&D framework, raising investment in WA, and take questions from the audience.

Proteomics International (ASX: PIQ; Perth, Western Australia) is at the forefront of predictive diagnostics and bio-analytical services. Proteomics International's business model centres on the commercialisation of the company's world-leading predictive test for diabetic kidney disease, PromarkerD. The company offsets the cash burn from R&D and product development through provision of specialist analytical services across the globe, whilst using its proprietary Promarker® technology platform to create a pipeline of novel diagnostic tests.

Richard Lipscombe is a protein chemist by training having completed his chemistry degree at Oxford University and a Doctorate in Immunology at London University. Richard moved to Perth in 1995 and managed the Protein Analysis Facility at the University of Western Australia, before stepping out of academia to co-found Proteomics International in 2001. Richard's career has focused on industry-based research and the translation of innovative technology into commercial products and services. Richard led the company through its ASX listing in 2015 and now heads the corporate development and the commercialisation of its ground-breaking technologies. He is an inventor of several patents and, almost uniquely, has taken a protein biomarker from concept to commercial diagnostic test, with the company's pioneering prognostic test for diabetic kidney disease, PromarkerD, now in the clinic.

The event runs from 7:30am – 9am AWST at the Harry Perkins Institute for Medical Research in Perth.

We hope you can join us, register today.